Well, their POC tests function on an antiquated platform. CEMI is really a platform company, not a diagnostics company. Alere has held lateral flow patent technology for many years now (soon expiring), and they are working on future technologies, but they don't have DPP, which CEMI is going to license far and wide.
If they get a CLIA waiver for DPP HIV and if they have an Ebola and multiplex with Ebola in the next few months.
My question: where is CEMI going to get the cash for all the Ebola work. I'm assuming government grants are forthcoming.
All that said, their bread and butter is DPP HIV, Syphilis, and HCV. Work in those areas must continue and the FDA must be reasonable on CLIA waivers for these products.
Mr. "protect the investment" (remember that LS classic) was a "dumb" seller under $4. I'd expect no less from the brilliant Larry Siebert.
Huh? I'm in the 99% when it comes to individual investors, and I'm a big investor in CEMI. My approach is always to battle test my ideas but making my concerns public.
Of course, there are lots of missing details. Antigens?
I'm going to go out on a limb and say that they have or will soon have everything they need to develop a test, and that an actual test will arrive very soon. It's possible that trials are imminent or already underway. There is another company running trials right now. I don't think an Ab test would be terribly useful, so this must be an antigen test.
What's different about DPP is the multiplex capability and, equally important, the storage conditions, which I assume are RT. That's an important bit of information which we don't yet have.
I'm sure Mo and the gang will still refuse to take down the LS Fatheads from their bedroom walls (which happen to be in their parents' basements).
"Larrys primary role has been as an investor and will continue to be so. Of course as an investor he will do everything to promote the growth of the company."
His recent stock sale puts the lie to what he told you last year.
CEMI's DPP platform is far superior. Not saying CEMI is working on Ebola. Don't know, as CEMI has been very quiet on the subject.
OSUR has been tooting the Ebola horn as loud as it possibly can. Unseemly.
Regarding the syphilis test, the FDA changed the algo on TRIB, a move which caused CEMI to have to completely overhaul its syphilis test for the US market. I'm sure TRIB is trying to claim some sort of grandfather exception. Who knows if that works or not. However, CEMI was told "no" definitively.
TRIB's US HIV sales could take a hit if and when ALR get's a CLIA waiver for its Determine Combo Ag/Ab test. Ditto if CEMI gets a waiver for its DPP HIV test.
After the troponin bobble, I'd be a bit worried about management execution. Just sayin'
They should dump all the detailing businesses, for whatever they can get. I've been advocating that for years. I don't necessarily believe that molecular diagnostics is a bad direction, but you've got to have people who are familiar with this business.
People come to this board in good faith looking for solid information about this company and, then, they encounter your grade F posts. Your presence here is hurting the company and hurting the stock price. Just go away.
Just go away. You do a disservice to all who come here trying to understand this company and sector.
JUST GO AWAY.
Yup. Now, we'll be lucky to get it at all. If they don't get it, the FDA is essentially saying, we'd rather continue on with an inferior lateral flow oral fluid monopoly indefinitely, and never have multiplex testing in the US.
First of all, it's moderately complex, bonehead. Second, failure to receive the waiver is not OKAY for a product the main function of which is to allow for widely distributed and off-site testing. Without the CLIA waiver, there's really not much point in having a POC diagnostic product. The fact that you don't know any of this after all this time is truly SHOCKING.
The future outlined by NL is a non-starter. Hence, a new CFO who is likely calling all the shots at this point. We haven't yet heard what the new plan will be, but it obviously can't be the old one because that's bankruptcy. I'm guessing asset sales and/or a sale of the entire company.